Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26


Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis.

Redig J, Dalén J, Harmenberg U, Lindskog M, Ljungberg B, Lundstam S, Sandin R, Wahlgren T, Åkerborg Ö, Jakobsson M.

Cancer Manag Res. 2019 Feb 8;11:1289-1297. doi: 10.2147/CMAR.S188849. eCollection 2019.


Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial.

Jakola AS, Werlenius K, Mudaisi M, Hylin S, Kinhult S, Bartek J Jr, Salvesen Ø, Carlsen SM, Strandéus M, Lindskog M, Löfgren D, Rydenhag B, Carstam L, Gulati S, Solheim O, Bartek J, Solheim T.

F1000Res. 2018 Nov 15;7:1797. doi: 10.12688/f1000research.16786.1. eCollection 2018.


Cancer patients hospitalised in the last week of life risk insufficient care quality - a population-based study from the Swedish Register of Palliative Care.

Elmstedt S, Mogensen H, Hallmans DE, Tavelin B, Lundström S, Lindskog M.

Acta Oncol. 2019 Apr;58(4):432-438. doi: 10.1080/0284186X.2018.1556802. Epub 2019 Jan 11.


Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.

Stenman M, Staehler M, Szabados B, Sandström P, Laurell A, Lindskog M, Harmenberg U.

Acta Oncol. 2019 Mar;58(3):306-312. doi: 10.1080/0284186X.2018.1537505. Epub 2018 Dec 3.


First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.


Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.

Lindskog M, Wahlgren T, Sandin R, Kowalski J, Jakobsson M, Lundstam S, Ljungberg B, Harmenberg U.

Urol Oncol. 2017 Sep;35(9):541.e15-541.e22. doi: 10.1016/j.urolonc.2017.05.013. Epub 2017 Jun 13.


Heed or disregard a cancer patient's critical blogging? An experimental study of two different framing strategies.

Lynøe N, NattochDag S, Lindskog M, Juth N.

BMC Med Ethics. 2016 May 20;17(1):30. doi: 10.1186/s12910-016-0115-3.


Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma.

Thorstenson A, Harmenberg U, Lindblad P, Ljungberg B, Lundstam S; Swedish Kidney Cancer Quality Register Group.

Scand J Urol. 2016;50(1):2-8. doi: 10.3109/21681805.2015.1059882. Epub 2015 Jul 23.


Old age as risk indicator for poor end-of-life care quality - a population-based study of cancer deaths from the Swedish Register of Palliative Care.

Lindskog M, Tavelin B, Lundström S.

Eur J Cancer. 2015 Jul;51(10):1331-9. doi: 10.1016/j.ejca.2015.04.001. Epub 2015 May 6.


Glycaemic control in end-of-life care.

Lindskog M, Kärvestedt L, Fürst CJ.

Curr Opin Support Palliat Care. 2014 Dec;8(4):378-82. doi: 10.1097/SPC.0000000000000095. Review.


Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma.

Stenman M, Laurell A, Lindskog M.

Med Oncol. 2014 Mar;31(3):841. doi: 10.1007/s12032-014-0841-7. Epub 2014 Jan 30.


Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.

Sörenson S, Fohlin H, Lindgren A, Lindskog M, Bergman B, Sederholm C, Ek L, Lamberg K, Clinchy B.

Eur J Cancer. 2013 Jan;49(1):115-20. doi: 10.1016/j.ejca.2012.07.032. Epub 2012 Aug 27.


Fish oil delays lymphoma progression in the TLL mouse.

Johansson AS, Norén-Nyström U, Larefalk A, Holmberg D, Lindskog M.

Leuk Lymphoma. 2010 Nov;51(11):2092-7. doi: 10.3109/10428194.2010.522284. Epub 2010 Oct 4.


Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo.

Gleissman H, Segerström L, Hamberg M, Ponthan F, Lindskog M, Johnsen JI, Kogner P.

Int J Cancer. 2011 Apr 1;128(7):1703-11. doi: 10.1002/ijc.25473. Epub 2010 May 24.


Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.

Felth J, Rickardson L, Rosén J, Wickström M, Fryknäs M, Lindskog M, Bohlin L, Gullbo J.

J Nat Prod. 2009 Nov;72(11):1969-74. doi: 10.1021/np900210m.


Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates.

Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI, Kogner P.

FASEB J. 2010 Mar;24(3):906-15. doi: 10.1096/fj.09-137919. Epub 2009 Nov 4.


Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide.

Johansson AS, Pawelzik SC, Larefalk A, Jakobsson PJ, Holmberg D, Lindskog M.

Leuk Lymphoma. 2009 Jul;50(7):1198-203. doi: 10.1080/10428190902946930.


Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.

Palmberg E, Johnsen JI, Paulsson J, Gleissman H, Wickström M, Edgren M, Ostman A, Kogner P, Lindskog M.

Int J Cancer. 2009 Mar 1;124(5):1227-34. doi: 10.1002/ijc.24069.


The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.

Wickström M, Johnsen JI, Ponthan F, Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson K, Lewensohn R, Kogner P, Larsson R, Gullbo J.

Mol Cancer Ther. 2007 Sep;6(9):2409-17.


Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress.

Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI.

Int J Cancer. 2006 May 15;118(10):2584-93.

Supplemental Content

Loading ...
Support Center